KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $1.1 billion.

  • Vertex Pharmaceuticals' Free Cash Flow fell 1247.98% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 billion, marking a year-over-year increase of 40179.06%. This contributed to the annual value of -$790.3 million for FY2024, which is 12368.37% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Free Cash Flow stood at $1.1 billion for Q3 2025, which was down 1247.98% from $927.4 million recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year Free Cash Flow high stood at $1.3 billion for Q3 2024, and its period low was -$3.8 billion during Q2 2024.
  • Its 5-year average for Free Cash Flow is $617.1 million, with a median of $901.3 million in 2022.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Free Cash Flow surged by 53529.65% in 2022 and then crashed by 45565.69% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' Free Cash Flow (Quarter) stood at $933.2 million in 2021, then rose by 11.96% to $1.0 billion in 2022, then tumbled by 83.11% to $176.5 million in 2023, then soared by 178.75% to $492.0 million in 2024, then surged by 131.63% to $1.1 billion in 2025.
  • Its Free Cash Flow stands at $1.1 billion for Q3 2025, versus $927.4 million for Q2 2025 and $778.2 million for Q1 2025.